A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.
As Trump’s health officials push personal responsibility, critics warn their rhetoric blames patients, shapes policy, and risks deepening health inequalities.
Researchers assess how disease type, comorbidities, and treatment knowledge shape clinical outcomes and healthcare use in patients with chronic urticaria.
New research has documented 4 cases of lip basal cell carcinoma presenting as smooth yellow nodules—a rare clinical presentation that may be mistaken for benign mesenchymal tumors, potentially resulting in diagnostic delays and postponed treatment.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
New clinical recommendations detail updated vaccination and screening protocols to reduce infection and cancer risks in adults with inflammatory bowel disease, particularly those on immune-modifying therapies.